明朝医圣李时珍本草纲目药方大全 - 本草纲目全书
Published by:
小丽 黄
Description
《本草纲目》，药学著作，五十二卷，明·李时珍撰，刊于1590年。
全书共190多万字，载有药物1892种，收集医方11096个，绘制精美插图1160幅，分为16部、60类。
李时珍在继承和总结以前本草学成就的基础上，结合长期学习、采访所积累的大量药学知识，经过实践和钻研，历时数十年而编成的一部巨著。
《本草纲目》中不仅考正了过去本草学中的若干错误，综合了大量科学资料，提出了较科学的药物分类方法，溶入先进的生物进化思想，并反映了丰富的临床实践。
《本草纲目》不仅仅是我国明代的一部杰出的药物学著作，也是一部集16世纪以前中国本草学之大成的药典，对我国近代药物学的发展有着不可估量的推动作用，在世界范围内也有着极佳的声誉，被誉为“东方药物巨典”。
Hide
Show More...
全书共190多万字，载有药物1892种，收集医方11096个，绘制精美插图1160幅，分为16部、60类。
李时珍在继承和总结以前本草学成就的基础上，结合长期学习、采访所积累的大量药学知识，经过实践和钻研，历时数十年而编成的一部巨著。
《本草纲目》中不仅考正了过去本草学中的若干错误，综合了大量科学资料，提出了较科学的药物分类方法，溶入先进的生物进化思想，并反映了丰富的临床实践。
《本草纲目》不仅仅是我国明代的一部杰出的药物学著作，也是一部集16世纪以前中国本草学之大成的药典，对我国近代药物学的发展有着不可估量的推动作用，在世界范围内也有着极佳的声誉，被誉为“东方药物巨典”。
Screenshots
明朝医圣李时珍本草纲目药方大全 FAQ
-
Is 明朝医圣李时珍本草纲目药方大全 free?
Yes, 明朝医圣李时珍本草纲目药方大全 is completely free and it doesn't have any in-app purchases or subscriptions.
-
Is 明朝医圣李时珍本草纲目药方大全 legit?
Not enough reviews to make a reliable assessment. The app needs more user feedback.
Thanks for the vote -
How much does 明朝医圣李时珍本草纲目药方大全 cost?
明朝医圣李时珍本草纲目药方大全 is free.
-
What is 明朝医圣李时珍本草纲目药方大全 revenue?
To get estimated revenue of 明朝医圣李时珍本草纲目药方大全 app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.
User Rating
1 out of 5
1 ratings in Australia
5 star
0
4 star
0
3 star
0
2 star
0
1 star
1
Ratings History
明朝医圣李时珍本草纲目药方大全 Reviews
Store Rankings
Ranking History
App Ranking History not available yet
Category Rankings
App is not ranked yet
明朝医圣李时珍本草纲目药方大全 Installs
Last 30 days
明朝医圣李时珍本草纲目药方大全 Revenue
Last 30 days明朝医圣李时珍本草纲目药方大全 Revenue and Downloads
Gain valuable insights into 明朝医圣李时珍本草纲目药方大全 performance with our analytics.
Sign up now to access downloads, revenue, and more.
Sign up now to access downloads, revenue, and more.
App Info
- Category
- Medical
- Publisher
- 小丽 黄
- Languages
- English
- Recent release
- 1.0 (9 years ago )
- Released on
- Dec 1, 2015 (9 years ago )
- Also available in
- China, United States, Taiwan, Canada, Malaysia, Japan, Australia, Thailand, Philippines, Romania, Peru, New Zealand, Norway, Netherlands, Nigeria, Mexico, Lebanon, Kazakhstan, Pakistan, Poland, Portugal, South Africa, Russia, Saudi Arabia, Sweden, Türkiye, Ukraine, Vietnam, United Arab Emirates, Dominican Republic, Argentina, Austria, Azerbaijan, Belgium, Bulgaria, Brazil, Belarus, Switzerland, Colombia, Czechia, Germany, Denmark, Kuwait, Ecuador, Egypt, Spain, Finland, United Kingdom, Greece, Indonesia, Ireland, Israel, Italy, South Korea
- Last Updated
- 2 weeks ago
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.